MedTrace Logo

Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease

NCT07496021 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-30

No results posted yet for this study

Summary

Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease

Conditions

  • Early Alzheimers Disease

Interventions

DRUG

L. lactis CKDB001

Oral Capsule

DRUG

Placebo

Oral Capsule

Sponsors & Collaborators

  • CKD Bio Corporation

    lead INDUSTRY

Principal Investigators

  • Woo Jung Kim · Yonsei University Yongin Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-23
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07496021 on ClinicalTrials.gov